Enhancing clinical decision-making: An externally validated machine learning model for predicting isocitrate dehydrogenase mutation in gliomas using radiomics from presurgical magnetic resonance imaging
Open Access
- 1 January 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 6 (1) , vdae157
Abstract
Background: Glioma, the most prevalent primary brain tumor, poses challenges in prognosis, particularly in the high-grade subclass, despite advanced treatments. The recent shift in tumor classification underscores the crucial role of isocitrate dehydrogenase (IDH) mutation status in the clinical care of glioma patients. However, conventional methods for determining IDH status, including biopsy, have limitations. Exploring the use of machine learning (ML) on magnetic resonance imaging to predict IDH mutation status shows promise but encounters challenges in generalizability and translation into clinical practice because most studies either use single institution or homogeneous datasets for model training and validation. Our study aims to bridge this gap by using multi-institution data for model validation. Methods: This retrospective study utilizes data from large, annotated datasets for internal (377 cases from Yale New Haven Hospitals) and external validation (207 cases from facilities outside Yale New Haven Health). The 6-step research process includes image acquisition, semi-automated tumor segmentation, feature extraction, model building with feature selection, internal validation, and external validation. An extreme gradient boosting ML model predicted the IDH mutation status, confirmed by immunohistochemistry. Results: The ML model demonstrated high performance, with an Area under the Curve (AUC), Accuracy, Sensitivity, and Specificity in internal validation of 0.862, 0.865, 0.885, and 0.713, and external validation of 0.835, 0.851, 0.850, and 0.847. Conclusions: The ML model, built on a heterogeneous dataset, provided robust results in external validation for the prediction task, emphasizing its potential clinical utility. Future research should explore expanding its applicability and validation in diverse global healthcare settings.Keywords
Funding Information
- Heinrich-Heine-University
- American Society of Neuroradiology Fellow (KL2 TR001862)
- National Center for Advancing Translational Science
- National Institutes of Health
- NIH Roadmap for Medical Research
- Investigative Medicine Program
- CTSA (UL1 TR001863)
- National Center for Advancing Translational Science
- MingDe Lin
- Visage Imaging, Inc.
- NCI (R01 CA206180)
- Tau Beta Pi Engineering Honor Society
This publication has 50 references indexed in Scilit:
- Somatic mutations associated with MRI-derived volumetric features in glioblastomaNeuroradiology, 2015
- Molecular Heterogeneity in Glioblastoma: Potential Clinical ImplicationsFrontiers in Oncology, 2015
- Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomasOncotarget, 2014
- Glioblastoma Heterogeneity and Cancer Cell PlasticityCritical Reviews™ in Oncogenesis, 2014
- Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from ChinaJournal of Cancer Research and Clinical Oncology, 2013
- Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomasActa Neuropathologica, 2010
- Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain TumorsBrain Pathology, 2009
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Malignant Gliomas in AdultsNew England Journal of Medicine, 2008
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005